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Abstract: Background: Little is known about the outcome of patients with 
MS undergoing transcatheter aortic valve replacement (TAVR). Therefore, 
we sought to evaluate the potential impact of MS on the outcome of 
patients who underwent TAVR using the US national cohort. 
 
Method: Using weighted data from the National Inpatient Sample (NIS) 
database between 2011 and 2015, we identified patients who had undergone 
a TAVR as a primary procedure. Patients with MS diagnosis were compared 
to those without MS. Univariate and multivariate logistic regression 
analysis were performed for the outcomes of in-hospital mortality and 
post-procedural complications. Outcomes were also stratified by the type 
to TAVR (endovascular versus transapical). 
 
Results: A total of 62,110 patients underwent TAVR (mean age 81 ± 8.72, 
47.4% females, and 3.7% African Americans) and 887 patients had MS 
(1.43%). Patients with concomitant MS had higher in-hospital mortality 
(5.1% vs 3.5% adjusted Odds Ratio [aOR], 1.455; 95% confidence interval 
[CI], 1.059-2.001, P=0.021), major adverse cardiac events (MACE) (9.0% vs 
7.1% aOR, 1.297; 95% CI, 1.012-1.663, P=0.040), major bleeding (16.3% vs 
12.1% aOR, 1.303; 95% CI, 1.067-1.593, P=0.010), cardiac complications 
(21.8% vs 16.0% aOR, 1.536; 95% CI, 1.300-1.815, P<0.001) and acute 
myocardial infarction (AMI) (4.5% vs 2.8% aOR, 1.783; 95% CI, 1.249-
2.545, P=0.007) when compared with patients without MS. 
 
Conclusion: Mitral stenosis is an independent risk factor for mortality 
and morbidity after TAVR procedure for patients with severe AS. 
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Abstract 
Background: Little is known about the outcome of patients with MS undergoing transcatheter 
aortic valve replacement (TAVR). Therefore, we sought to evaluate the potential impact of MS 
on the outcome of patients who underwent TAVR using the US national cohort. 
Method: Using weighted data from the National Inpatient Sample (NIS) database between 2011 
and 2015, we identified patients who had undergone a TAVR as a primary procedure. Patients 
with MS diagnosis were compared to those without MS. Univariate and multivariate logistic 
regression analysis were performed for the outcomes of in-hospital mortality and post-
procedural complications. Outcomes were also stratified by the type to TAVR (endovascular 
versus transapical). 
Results: A total of 62,110 patients underwent TAVR (mean age 81  8.72, 47.4% females, and 
3.7% African Americans) and 887 patients had MS (1.43%). Patients with concomitant MS had 
higher in-hospital mortality (5.1% vs 3.5% adjusted Odds Ratio [aOR], 1.455; 95% confidence 
interval [CI], 1.059-2.001, P=0.021), major adverse cardiac events (MACE) (9.0% vs 7.1% aOR, 
1.297; 95% CI, 1.012-1.663, P=0.040), major bleeding (16.3% vs 12.1% aOR, 1.303; 95% CI, 
1.067-1.593, P=0.010), cardiac complications (21.8% vs 16.0% aOR, 1.536; 95% CI, 1.300-
1.815, P<0.001) and acute myocardial infarction (AMI) (4.5% vs 2.8% aOR, 1.783; 95% CI, 
1.249-2.545, P=0.007) when compared with patients without MS. 
Conclusion: Mitral stenosis is an independent risk factor for mortality and morbidity after TAVR 
procedure for patients with severe AS. 
Introduction: 
Transcatheter aortic valve replacement (TAVR) is now the standard of care for patients with 
severe aortic valve stenosis (AS) who are at high and intermediate risk for surgical aortic valve 
replacement (SAVR) 1-5.  The coexistence of mitral stenosis (MS) and aortic stenosis (AS) is far 
from being exceptional in SAVR. Current registries suggest a prevalence of 11.6% of mitral 
stenosis in patients undergoing TAVR 6. In one study, 17% of patients referred for aortic valve 
replacement were found to have mitral stenosis 7 with double valve surgery associated with 
higher operative mortality and lower long-term survival rates compared with those undergoing 
isolated aortic valve replacement 7,8. Furthermore, the risk of thromboembolism is higher in 
patients undergoing double valve replacement compared with patients undergoing isolated 
aortic valve replacement 9.  
The periprocedural hemodynamic effect of mitral stenosis in patients undergoing TAVR is not 
well understood. Although mitral regurgitation has been an established risk factor for increased 
morbidity and mortality in TAVR patients 10,11, there is limited data regarding the outcome of 
TAVR patients with concomitant aortic stenosis and mitral stenosis. Many explanations have 
been proposed for the effect of MS on left ventricular (LV) hemodynamics including reduction in 
LV filling, reduction of LV compliance and diastolic dysfunction, increased afterload, and 
pulmonary hypertension 12,13 leading to potentially increased cardiovascular and overall 
morbidity and mortality. Furthermore, the presence of mitral annular calcification was associated 
with a higher overall and cardiac mortality, along with post-procedural morbidity 14. Therefore, 
we sought to evaluate the impact of mitral stenosis on the in-hospital outcome of patients 
undergoing TAVR using the National Inpatient Sample (NIS).  
Method: 
Patient selection 
Using the NIS database from 2011 to 2015, we performed a retrospective analysis. The NIS is a 
publicly available identified database of hospital discharges in the United States, containing data 
from approximately 8 million hospital stays that were selected using a complex probability 
sampling design and the weighting scheme recommended by the Agency for Healthcare 
Research and Quality which is intended to represent all discharges from nonfederal hospitals. 
Each record includes one primary diagnosis and up to 24 secondary diagnoses from 2011 to 
2014 and up to 29 secondary diagnoses from 2014 to 2015. After weighing the data, we 
identified 62,110 adult patients who had undergone TAVR as a primary procedure using the 
International Classification of Disease, Ninth Edition, Clinical Modification (ICD-9-CM) codes 
(35.05 and 35.06), out of which 887 patients with MS diagnosis (regardless of etiology) using 
the codes (394.0 and 396.0). Patients with concomitant mitral valve repair were excluded. Using 
the Clinical Classification Software codes provided by the Healthcare Cost and Utilization 
Project and the Elixhauser Comorbidity Index, comorbidities were appointed via ICD-9 codes. 
Supplemental table 1 identifies comorbidities from the Elixhauser comorbidity index, and ICD-9 
codes used for other comorbidities and in-hospital outcomes. Institutional board review approval 
is not required as the NIS is a publicly available database. 
Outcomes 
The primary outcome of the study was in-hospital mortality. The secondary outcomes were in-
hospital complications which included hemorrhage requiring blood transfusion,  vascular 
complications (injury to blood vessels, accidental puncture, injury to retroperitoneum, other 
vascular complications, vascular complications requiring surgery), cardiac complications 
(iatrogenic cardiac complications, hemopericardium, cardiac tamponade and 
pericardiocentesis), permanent pacemaker (PPM) implantation, conversion to open-heart 
surgery, respiratory complications (post-procedural pneumothorax, post-procedural pulmonary 
edema, pulmonary collapse, prolonged mechanical ventilation >96 hours, tracheostomy), post-
procedural stroke, and acute kidney injury (AKI). All procedure-related complications were 
identified using appropriate ICD-9- CM codes (Supplementary Table 1). 
Statistical analysis 
The data was expressed as weighted mean values ± standard deviation, and frequencies were 
denoted in percentages according to the presence or absence of MS. Independent t-tests were 
used for the comparison of continuous variables measurements, while chi-square test for 
categorical variables. Weighted values of patient level observations were generated to produce 
a nationally representative estimate of the entire US population of hospitalized patients. 
Univariable and multiple logistic regressions were used to study the association between the 
MS and the primary and secondary outcomes after TAVR. The regression models were 
adjusted for demographics (age, race and gender), urgency of TAVR (elective versus 
emergent), included Elixhauser comorbidities (other than valvular disorders), other relevant 
comorbidities (atrial fibrillation, smoking, carotid artery disease, coronary artery disease, prior 
stroke and dyslipidemia), TAVR access (endovascular or transapical), patient insurance, 
socioeconomic status and hospital characteristics. Linear regression models were used to 
assess the length of stay (LOS). Log transformation of LOS was used to adjust for positively 
skewed data. We performed a subgroup analysis by further stratifying patients for TAVR access 
for all outcomes. To further explore our findings, we performed multivariate logistic regression 
for the predictors of having MS in patients who underwent TAVR. For the trend analysis, 
Cochrane-Armitage test was used to determine the presence of a linear trend in MS rates in 
patients who underwent TAVR during the studied years. P-value of less than 0.05 was 
considered statistically significant. SPSS version 25 software (IBM Corp, Armonk, NY) was used 
for all statistical analyses. 
Results: 
Baseline Characteristics  
During the study period, a total of 62,110 patients underwent TAVR (mean age 81  8.72, 
47.4% females, and 3.7% African Americans). We identified 887 patients with MS (1.43%) and 
compared them with 61,233 (98.57%) patients without MS. Patients in the MS group were 
younger (79.10 vs 81.02, P < 0.001) more females (65.6% vs 47.2%) and African American 
patients (7.9% vs 3.9%) (P < 0.001 for both). Furthermore, the MS group had a lower burden of 
several comorbidities including hypertension (HTN), coronary artery disease (CAD), rheumatoid 
arthritis, psychosis and hyperlipidemia (HLD) (P < 0.001). However, other comorbid conditions 
such as diabetes mellitus (DM), deficiency anemia, chronic pulmonary disease, hypothyroidism, 
fluid and electrolyte disorders, peripheral vascular disease (PAD) and pulmonary circulation 
disorders were more prevalent in the MS group. Baseline characteristics stratified by MS status 
is described in table 1.  
In patients who underwent TAVR, and using multivariate logistic regression, female gender, 
African American race, complicated and uncomplicated diabetes mellitus, fluid and electrolyte 
disorders, peripheral vascular disease, pulmonary circulation disorders and renal failure were 
identified as predictors of having MS (P  0.049 for all). Female gender and pulmonary 
circulation disorders had the highest odds of having MS (OR, 2.178; 95% CI, 1.862-2.547, P < 
0.001), (OR, 2.319; 95% CI, 1.589-3.384, P < 0.001), respectively (table 3). Younger patients 
were more likely to have MS (OR, 0.979; 95% CI, 0.971-0.988, P < 0.001). 
Using the Cochrane-Armitage method, there was a statistically significant linear increase in the 
rate of MS patients undergoing TAVR from 1.0% to 1.6% between the years of 2011 and 2014 
(P < 0.001) (figure 3). 
In-hospital Outcomes 
Following adjustment for baseline covariates, patients with MS had a statistically significant 
higher in-hospital mortality compared to the non-MS group after adjusting for patients’ 
demographics, TAVR access, urgency, comorbidities, patient insurance, socioeconomic status 
and hospital characteristics (5.1% vs 3.5% adjusted Odds Ratio [aOR], 1.455; 95% confidence 
interval [CI], 1.059-2.001, P = 0.021) (Figure 1). Furthermore, MS patients had a statistically 
significant higher major adverse cardiac events (MACE) (9.0% vs 7.1% aOR, 1.297; 95% CI, 
1.012-1.663, P=0.040), major bleeding (16.3% vs 12.1% aOR, 1.303; 95% CI, 1.067-1.593, 
P=0.010), cardiac complications (21.8% vs 16.0% aOR, 1.536; 95% CI, 1.300-1.815, P<0.001), 
and acute myocardial infarction (AMI) (4.5% vs 2.8% aOR, 1.783; 95% CI, 1.249-2.545, 
P=0.007) when compared with non-MS patients. Interestingly, MS patients had statistically 
significant lower vascular complications when compared with non-MS patients (2.3% vs 3.7% 
aOR, 0.487; 95% CI, 0.308-0.768, P=0.002) (figure 2). Risk-adjusted linear regression for length 
of stay demonstrated no statistically significant difference in length of stay between MS and 
non-MS groups (P=0.553). The rates of PPM placement, respiratory complications, post-
procedural stroke and conversion open heart surgery were comparable in both groups (Table 
2).  
Upon further stratifying the analysis by TAVR access, patients with MS undergoing 
endovascular TAVR had statistically significant higher in-hospital mortality (aOR 1.495; 95% CI, 
1.016-2.095, P=0.041), major bleeding (aOR 1.329; 95% CI, 1.072-1.593, P=0.009), cardiac 
complications (aOR 1.462; 95% CI, 1.217-1.757, P < 0.001), AMI (aOR 1.700; 95% CI, 1.156-
2.502, P=0.007). In addition, MS patients undergoing transapical TAVR had statistically 
significant higher cardiac complications (aOR 1.756; 95% CI, 1.1156-2.668, P=0.008), 
respiratory complications (aOR 1.874; 95% CI, 1.254-2.801, P=0.002) and acute kidney injury 
(aOR 3.769; 95% CI, 2.502-5.676, P < 0.001) when compared with non-MS patients. 
Discussion: 
In our national analysis of TAVI patients, we found that a small proportion (1.4%) to have mitral 
stenosis. The rates of mitral stenosis in this population with TAVR have been increasing over 
time from 1.0% to 1.6%. Furthermore, these patients with MS who undergo TAVR are more 
likely to be younger, female, African American and more likely to have diabetes mellitus, 
peripheral vascular disease, pulmonary circulation disorders and fluid and electrolyte disorder. 
Patients who underwent TAVR with MS had higher in-hospital mortality and adverse outcomes 
compared to patients without MS. These findings suggest that patients with MS who undergo 
TAVR are a high risk group, and measure for improving outcomes in this population is needed. 
Patients who are referred for a TAVR procedure are often older and have more cardiovascular 
comorbidities. Although patients with MS were significantly younger compared to those without 
MS, they had higher rates of DM, chronic pulmonary disease, pulmonary circulation disorders, 
PAD, and deficiency anemia. The proposed mechanism for MS-induced LV dysfunction is due 
to myocardial inflammation that occurs in the acute phase of rheumatic fever, and the chronic 
hemodynamics changes triggered by change in preloading conditions 12. Furthermore, MS has 
been frequently identified as a cause of elevated pulmonary artery pressure and pulmonary 
hypertension (PH) 15. The changes in the LV preload and PH could explain the elevated risk of 
cardiac complications and mortality since PH is already known to be an independent risk factor 
for morbidity and mortality in TAVR patients, which is consistent with our findings 16.  
The recently published work by Jospeh et al. 6 has demonstrated a higher in-hospital mortality in 
patients with severe MS who underwent TAVR, which supports our findings. In addition, the 1-
year mortality and the composite outcome of mortality, stroke, heart failure-related 
hospitalization and re-intervention of mitral disease were higher in both severe MS and non-
severe MS patients who underwent TAVR. We have added to these findings by demonstrating a 
higher MACE in MS patients compared with patients without MS. Interestingly, non-severe MS 
had no statistically significant difference in in-hospital mortality when compared with patients 
without MS. 
In TAVR, the retrograde aortic approach has increased odds of left ventricular perforation 
causing pericardial effusions 17,18. In our study, cardiac complications, including iatrogenic 
complications and cardiac tamponade, were significantly increased in MS patients compared 
with non-MS patients. Our population showed a rate of 21.8% in cardiac complications in those 
with MS compared to 16.0% in patients without MS. The increased risk of cardiac complications 
could be attributed to the LV dysfunction associated with MS 12. 
Our study showed that 4.5% of MS group suffered a post-procedural myocardial infarction 
compared with 2.8% in the non-MS group. Even after adjusting for potential cofounder, MS 
patients had almost 78% increased odds of AMI. Interestingly, previous literature had 
demonstrated the rate of AMI was comparable between MS and non-MS groups regardless of 
MS severity 6. 
Given our findings, we suggest a thorough pre-operative risk evaluation for MS patients 
requiring TAVR through hemodynamic evaluation. A possible expansion of hemodynamic 
assessment, especially in patients with clinical evidence of PH might improve the predictability 
of the procedural outcomes. The ACC/TAVI in-hospital mortality score has incorporated severe 
chronic pulmonary disease as predictor for worse outcomes in patients undergoing TAVR 19. 
More studies are needed to further identify measures to minimize the procedural risk associated 
with this high risk population. 
Our study has several limitations as it was a retrospective observational study, which poses a 
possible selection bias and unmeasured confounding factors. Moreover, the National Inpatient 
Sample is an administrative database which could be subject to inaccurate coding and 
underreporting of comorbid diagnoses. In addition, data regarding the severity of mitral valve 
stenosis and other relevant echo parameters were missing. Furthermore, details of the TAVR 
procedure were not reported such as; the type of device used, anesthesia type and the amount 
of contrast used which pose possible cofounding factors.  
Conclusions 
Mitral stenosis patients had higher in-hospital mortality in patients undergoing TAVR with 
increased risk of major bleeding, cardiac complications and acute myocardial infarction. Based 
on these findings, we propose assessment of hemodynamics prior to TAVR procedure 
especially in patients with echocardiographic evidence for MS. 
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TABLE 1. Baseline characteristics stratified by presence of MS. 
Variable 
MS 
(n=887) 
No MS 
(n=61,233)  
P-Value 
Age (meanSD) 79.10 ± 9.87 81.02 ± 8.70 <0.001 
Females, % 65.6 47.2 <0.001 
Race, %   <0.001 
White 85.5 87.4  
Black 7.9 3.9  
Hispanic 2.4 4.0  
Asian or pacific islander 1.8 1.1  
Native American 0.0 0.2  
Other 2.4 3.4  
Elective hospitalization, % 75.0 76.6 0.599 
Primary expected payer, %   0.012 
Medicare 90.4 90.1  
Medicaid 1.7 1.1  
Private insurance 7.3 7.0  
Self-pay 0.6 0.5  
No Charge 0.0 0.0  
Other 0.0 1.3  
Median household income, %   0.230 
0 to 25 percentiles 21.0 19.9  
26 to 50 percentiles 24.8 23.3  
51 to 75 percentiles 25.9 28.8  
76 to 100 percentiles 28.2 28.0  
Bed size, %   0.914 
Small 4.5 4.8  
Medium 17.5 17.7  
Large 78.9 77.5  
Location/teaching status, %   0.300 
Rural  1.1 0.7  
Urban nonteaching 8.8 9.5  
Urban teaching 90.1 89.8  
Hospital region, %   <0.001 
Northeast 21.3 25.4  
Midwest 20.3 22.3  
South 34.9 33.8  
West 23.4 18.5  
TAVR access    
Endovascular access 1.2 84.3 0.076 
Transapical Access 0.2 15.9 0.055 
Comorbidities 
Hypertension, % 74.6 80.5 <0.001 
Diabetes, uncomplicated, % 34.9 29.2 <0.001 
Diabetes, complicated, % 7.3 6.0 0.107 
Hyperlipidemia, % 55.7 65.4 <0.001 
Smoking, % 2.8 3.2 0.486 
Table 1
Atrial fibrillation, % 41.6 44.2 0.127 
Prior stroke, % 14.1 13.1 0.385 
Carotid disease, % 6.8 7.4 0.446 
Coronary artery disease, % 57.9 68.9 <0.001 
Acquired immune deficiency, % 0.0 0.0 0.703 
Alcohol Abuse, % 0.6 1.1 0.124 
Deficiency anemia, % 30.1 24.8 <0.001 
Rheumatoid arthritis/collagen 
vascular disease, % 
6.2 4.7 0.039 
Chronic blood loss anemia, % 0.6 1.3 0.050 
Congestive heart failure, % 9.6 8.4 0.205 
Chronic pulmonary disease, % 36.6 33.0 0.024 
Coagulopathy, % 20.2 22.3 0.128 
Depression, % 9.0 7.5 0.080 
Drug abuse, % 0.6 0.3 0.161 
Hypothyroidism, % 25.8 20.3 <0.001 
Liver disease, % 3.4 2.6 0.150 
Lymphoma, % 0.6 1.3 0.051 
Fluid and electrolyte disorders, % 30.4 25.1 <0.001 
Metastatic cancer, % 0.0 0.4 0.057 
Solid tumor without metastasis, % 1.7 2.0 0.564 
Other neurological disorders, % 6.8 6.3 0.604 
Obesity, % 16.9 14.7 0.069 
Paralysis, % 2.3 1.7 0.233 
Psychosis, % 0.6 1.8 0.007 
Renal Failure, % 38.3 35.7 0.117 
Peripheral arterial disease, % 34.4 29.2 0.001 
Pulmonary circulation disorders, % 5.6 2.6 <0.001 
Peptic ulcer excluding bleeding, % 0.0 0.0 0.641 
Weight loss 4.5 4.7 0.813 
Abbreviations: MS – mitral stenosis; TAVR – transcatheter aortic valve replacement.  
 
TABLE 2. In-hospital outcomes of mitral stenosis patients who underwent TAVR when compared with those without mitral stenosis. 
Outcome MS Non-MS 
UOR (95% CI) MS 
(when compared 
with no MS) 
aOR (95% CI) MS 
(when compared 
with no MS) 
Unadjusted 
P-Value 
Adjusted 
P-Value 
Overall (n) 887 61,233     
Endovascular (n) 767 51,614     
Transapical (n) 120 9,738     
MACE 9.0% 7.1% 1.296 (1.028-1.634) 1.297 (1.012-1.663) 0.028 0.040 
Endovascular 8.5% 6.8% 1.264 (0.978-1.633) 1.240 (0.940-1.637) 0.073 0.128 
Transapical 12.5% 8.7% 1.507 (0.874-2.601) 1.759 (0.994-3.111) 0.140 0.052 
NACE 23.0% 19.7% 1.216 (1.039-1.424) 1.090 (0.917-1.295) 0.015 0.330 
Endovascular 23.4% 19.8% 1.233 (1.041-1.459) 1.183 (0.993-1.410) 0.015 0.060 
Transapical 20.8% 19.4% 1.094 (0.702-1.705) 0.981 (0.615-1.564) 0.702 0.935 
In-hospital mortality 5.1% 3.5% 1.474 (1.088-1.995) 1.455 (1.059-2.001) 0.012 0.021 
Endovascular 4.6% 3.2% 1.444 (1.025-2.034) 1.495 (1.016-2.095) 0.035 0.041 
Transapical 8.3% 5.2% 1.666 (0.866-3.202) 1.629 (0.809-3.277) 0.126 0.172 
Length of stay (iQR), days 5 (4-9) 5 (3-9)    0.553 
Endovascular 5 (4-8) 5 (3-8)    0.389 
Transapical 7.50 (5.25-13.50) 7 (5-12)    0.573 
Major Bleeding 16.3% 12.1% 1.404 (1.172-1.681) 1.303 (1.067-1.593) <0.001 0.010 
Endovascular 16.8% 12.3% 1.443 (1.192-1.747) 1.329 (1.072-1.684) <0.001 0.009 
Transapical 12.5% 11.5% 1.104 (0.640-1.903) NA 0.723 NA 
Vascular complications 2.3% 3.7% 0.601 (0.385-0.938) 0.487 (0.308-0.768) 0.025 0.002 
Endovascular 2.6% 3.9% 0.652 (0.417-1.019) 0.515 (0.325-0.816) 0.060 0.005 
Transapical 0.0% 2.4% NA NA NA NA 
Cardiac complications 21.8% 16.0% 1.461 (1.243-1.716) 1.536 (1.300-1.815) 0.082 <0.001 
Endovascular 20.6% 15.8% 1.379 (1.155-1.645) 1.462 (1.217-1.757) <0.001 <0.001 
Transapical 29.2% 16.8% 2.042 (1.373-3.038) 1.756 (1.156-2.668) <0.001 0.008 
AMI 4.5% 2.8% 1.669 (1.211-2.300) 1.783 (1.249-2.545) 0.002 0.001 
Endovascular 4.6% 2.8% 1.683 (1.194-2.372) 1.700 (1.156-2.502) 0.003 0.007 
Transapical 4.2% 2.7% 1.591 (0.644-3.929) 2.203 (0.820-5.919) 0.314 0.117 
Permanent pacemaker 
implantation 
11.6% 10.4% 1.129 (0.918-1.389) 1.219 (0.984-1.512) 0.250 0.070 
Endovascular 12.1% 11.1% 1.100 (0.884-1.369) 1.204 (0.960-1.511) 0.392 0.109 
Transapical 8.3% 6.6% 1.297 (0.675-2.490) 1.280 (0.652-2.516) 0.435 0.473 
Open heart surgery 2.8% 2.1% 1.379 (0.923-2.061) 1.292 (0.858-1.946) 0.116 0.220 
Endovascular 3.3% 2.1% 1.560 (1.043-2.335) 1.497 (0.991-2.260) 0.031 0.055 
Transapical 0.0% 1.8% NA NA <0.001 NA 
Respiratory complications 15.2% 12.2% 1.290 (1.073-1.552) 1.172 (0.954-1.440) 0.007 0.131 
Endovascular 12.4% 10.4% 1.218 (0.981-1.513) 0.957 (0.747-1.226) 0.074 0.827 
Transapical 33.3% 22.0% 1.777 (1.212-2.606) 1.874 (1.254-2.801) 0.003 0.002 
Post-procedural stroke 1.1% 1.3% 0.864 (0.461-1.617) 0.623 (0.302-1.287) 0.647 0.201 
Endovascular 0.7% 1.3% 0.503 (0.208-1.217) 0.412 (0.158-1.071) 0.128 0.069 
Transapical 4.2% 1.4% 3.116 (1.252-7.753) 1.612 (0.278-9.345) 0.015 0.594 
Acute kidney injury  20.3% 17.6% 1.194 (1.013-1.408) 1.016 (0.836-1.235) 0.035 0.871 
Endovascular 16.3% 16.3% 0.999 (0.824-1.212) 0.705 (0.558-0.891) 0.995 0.003 
Transapical 45.8% 24.2% 2.645 (1.842-3.799) 3.769 (2.502-5.676) <0.001 <0.001 
Abbreviations: AMI – acute myocardial infarction; aOR – adjusted odds ratio; IQR – interquartile range; MS– mitral stenosis; MACE – major 
adverse cardiovascular events; NACE – net adverse cardiovascular events; TAVR – transcatheter aortic valve replacement; uOR – 
unadjusted odds ratio. Unadjusted odds ratios are displayed given low event rate. NA indicates odds ratio could not be calculated due to an 
event rate of 0% 
 
Table 2
 TABLE 3. The predictors of mitral stenosis in patients who underwent transcatheter aortic valve replacement.  
Predictor OR (95% CI)  P-Value 
Age 0.979 (0.971-0.988) <0.001 
Female Gender  2.178 (1.862-2.547) <0.001 
African American Race 1.674 (1.277-2.197) <0.001 
Uncomplicated Diabetes 1.375 (1.177-1.606) <0.001 
Complicated Diabetes  1.325 (1.001-1.755) 0.049 
Fluid and Electrolyte Disorders 1.182 (1.011-1.383) 0.036 
Peripheral Vascular Disease 1.395 (1.201-1.621) <0.001 
Pulmonary Circulation Disorders 2.319 (1.589-3.384) <0.001 
Renal Failure 1.205 (1.037-1.401) 0.015 
Abbreviations: OR– odds ratio; CI – confidence interval. 
Table 3
Figure 1. Multivariate logistic regression of the outcomes of transcatheter aortic valve 
replacement in patients with mitral stenosis compared with those without mitral stenosis. 
 
 
 
MACE – major adverse cardiovascular events; NACE – net adverse cardiovascular events; 
TAVR – transcatheter aortic valve replacement. 
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Figure 2. In-hospital outcomes rates in mitral Stenosis patients compared with non-mitral 
stenosis patients undergoing transcatheter aortic valve replacement. 
 
 
 
 
MACE – major adverse cardiovascular events; NACE – net adverse cardiovascular events; AMI 
– acute myocardial infarction. 
* Indicates statistical significance. 
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Figure 3. Trends in mitral stenosis rates in patients who underwent transcatheter aortic valve 
replacement. 
 
 
 
 
TAVR – transcatheter aortic valve replacement. 
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